PMID- 38216957
OWN - NLM
STAT- MEDLINE
DCOM- 20240127
LR  - 20240127
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 24
IP  - 1
DP  - 2024 Jan 12
TI  - Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic 
      factors in patients with major depressive disorder: a cross-sectional comparative 
      design.
PG  - 47
LID - 10.1186/s12888-023-05463-8 [doi]
LID - 47
AB  - BACKGROUND: Major depressive disorder (MDD) is a debilitating health condition 
      that has significant morbidity and mortality rates. Depression can be caused due 
      to social, biological, environmental, psychological, and genetic factors. A few 
      biological processes have been proposed as the pathophysiological pathways of 
      depression. Neurotrophic factors and inflammatory cytokines have been linked to 
      depression. Thus, we aimed to investigate the serum interleukin-33 (IL-33) and 
      mesencephalic astrocyte-derived neurotrophic factor (MANF) in MDD patients and 
      corresponding healthy controls (HCs). METHOD: This study involved the inclusion 
      of 129 MDD patients and 125 HCs matched by sex and age. A psychiatrist evaluated 
      the study participants following DSM-5 criteria. The severity of the illness was 
      assessed utilizing the Hamilton Depression Rating Scale (Ham-D). The serum 
      concentrations of IL-33 and MANF were measured using enzyme-linked immunosorbent 
      assay (ELISA) kits. RESULTS: The mean serum levels of IL-33 were decreased 
      (159.12 +/- 6.07 pg/ml vs. 180.60 +/- 8.64 pg/ml, p = 0.042), and the MANF levels 
      were increased (5.40 +/- 0.19 ng/ml vs. 4.46 +/- 0.21 ng/ml, p = 0.001) in MDD 
      patients when compared to HCs. CONCLUSIONS: The current study proposes that lower 
      IL-33 and higher MANF serum levels are associated with MDD progression and 
      depression severity. These biomarkers could be used as risk assessment tools for 
      MDD. We recommend more investigation, including a significant population, to 
      determine the precise function of IL-33 and MANF in depression.
CI  - (c) 2023. The Author(s).
FAU - Nahar, Zabun
AU  - Nahar Z
AD  - Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, 
      Dhaka, 1205, Bangladesh.
FAU - Nowshin, Delruba Tabassum
AU  - Nowshin DT
AD  - Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, 
      Dhaka, 1205, Bangladesh.
FAU - Roknuzzaman, A S M
AU  - Roknuzzaman ASM
AD  - Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, 
      Dhaka, 1205, Bangladesh.
FAU - Sohan, Md
AU  - Sohan M
AD  - Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, 
      Dhaka, 1205, Bangladesh.
FAU - Islam, Salsabil
AU  - Islam S
AD  - Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, 
      Dhaka, 1205, Bangladesh.
FAU - Qusar, M M A Shalahuddin
AU  - Qusar MMAS
AD  - Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Shahabagh, 
      Dhaka, 1000, Bangladesh.
FAU - Islam, Md Rabiul
AU  - Islam MR
AUID- ORCID: 0000-0003-2820-3144
AD  - School of Pharmacy, BRAC University, KHA 224, Progati Sarani, 1212, Merul Badda, 
      Dhaka, Bangladesh. robi.ayaan@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20240112
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
RN  - 0 (Interleukin-33)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (MANF protein, human)
RN  - 0 (IL33 protein, human)
SB  - IM
MH  - Humans
MH  - Astrocytes/metabolism
MH  - Cross-Sectional Studies
MH  - *Depressive Disorder, Major
MH  - Interleukin-33
MH  - Nerve Growth Factors/genetics/metabolism
PMC - PMC10785548
OTO - NOTNLM
OT  - Comparative design
OT  - Cross-sectional study
OT  - Cytokines
OT  - ELISA
OT  - IL-33
OT  - Interleukin-33
OT  - MANF
OT  - Major depressive disorder
OT  - Mesencephalic astrocyte derived neurotrophic factor
COIS- The authors declare no competing interests.
EDAT- 2024/01/13 00:42
MHDA- 2024/01/15 12:43
PMCR- 2024/01/12
CRDT- 2024/01/12 23:39
PHST- 2023/09/06 00:00 [received]
PHST- 2023/12/15 00:00 [accepted]
PHST- 2024/01/15 12:43 [medline]
PHST- 2024/01/13 00:42 [pubmed]
PHST- 2024/01/12 23:39 [entrez]
PHST- 2024/01/12 00:00 [pmc-release]
AID - 10.1186/s12888-023-05463-8 [pii]
AID - 5463 [pii]
AID - 10.1186/s12888-023-05463-8 [doi]
PST - epublish
SO  - BMC Psychiatry. 2024 Jan 12;24(1):47. doi: 10.1186/s12888-023-05463-8.